BI-671800 (compound A, 0.1-10 mg/kg, i.g.) shows significant inhibition of AHR in mice[1].
BI-671800 (compound A), effectively blocks edema formation and greatly reduces the inflammatory infiltrate and skin pathology observed in drug vehicle-treated animals[3].
| Animal Model: | 6-8-week-old age- and sex-matched BALB/c mice (mice were sensitized for 14 days, challenged intranasally)[1].
|
| Dosage: | 10-0.1 mg/kg |
| Administration: | Oral gavage for 4 weeks |
| Result: | Shows significant inhibition of AHR in mice. |
